Effect of Peroxisome Proliferator-Activated Receptors on Cardiac Remodeling in Normal and Diabetic Rats

Document Type : Original Article (s)

Authors

1 Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Associate Professor, Department of Anatomical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Peroxisome proliferator-activated receptors (PPARs) have three isoforms: β/δ, γ and α. It is indicated that peroxisome proliferator-activated receptors have different effects on cardiovascular system. In this study, we investigated the effect of these receptors on cardiac remodeling in normal and diabetic rats.Methods: 60 male rats were divided equally into normal and diabetic groups and each group was divided equally into following groups; saline (control), fenofibrate 100 mg/kg/day, rosiglitazone 8 mg/kg/day, GW0742 1 mg/kg/day and bezafibrate 400 mg/kg/day. After 21 days, the left ventricles were removed and stained with Picro-Sirius Red.Findings: Collagen content in left ventricles of diabetic animals (9.00 ± 1.27) were higher than controls (5.00±  1.13) (P < 0.05). Administration of peroxisome proliferator-activated receptor agonists did not alter interstitial fibrosis in control and diabetic groups (P > 0.05).Conclusion: Although, peroxisome proliferator-activated receptor agonists have several effects on cardiovascular system; it seems that they cannot alter cardiac remodeling in normal and diabetic animals.

Keywords

References

  1. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405(6785): 421-4.
  2. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358(6389): 771-4.
  3. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 2006; 45(1): 19-28.
  4. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85(5): 394-402.
  5. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393(6687): 790-3.
  6. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18(5): 269-76.
  7. Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002; 7(4): 219-26.
  8. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273(40): 25573-80.
  9. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83(11): 1097-103.
  10. Lazar MA. PPAR gamma, 10 years later. Biochimie 2005; 87(1): 9-13.
  11. Wang N. PPAR-delta in Vascular Pathophysiology. PPAR Res 2008; 2008: 164163.
  12. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003; 302(5644): 453-7.
  13. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4: 14.
  14. Remme WJ. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. Cardiovasc Drugs Ther 2003; 17(4): 349-60.
  15. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, et al. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 2007; 49(5): 1084-94.
  16. Silva-Junior GO, Torres TS, Mendonca LS, Mandarim-de-Lacerda CA. Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats. Exp Toxicol Pathol 2011; 63(1-2): 1-7.
  17. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154(2): 355-63.
  18. Katayama A, Yamamoto Y, Tanaka K, Matsubara K, Sugitani M, Fujihara S, et al. Fenofibrate enhances neovascularization in a murine ischemic hindlimb model. J Cardiovasc Pharmacol 2009; 54(5): 399-404.
  19. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 2004; 109(11): 1392-400.
  20. Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, Schwartz C, et al. Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res 2009; 83(1): 61-71.
  21. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 2008; 105(3): 985-90.
Journal of Isfahan Medical School
Volume 32, Issue 302 - Serial Number 302
July and August 2014
Pages 1530-1536

Files

History

  • Receive Date: 12 April 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics